Paper Details

  1. Home
  2. Paper Details

Interferon Beta-1b and Lopinavir-Ritonavir for Middle East Respiratory Syndrome.

Author: , AbdelzaherMohamed, Al BshabsheAli, Al FarajSarah, Al HarbiShmeylan, Al JeraisyMajed, Al JohaniSameera, Al MekhlafiGhaleb A, Al SaediAsim, Al-DawoodAbdulaziz, Al-HameedFahad, AlMutairiBadriah M, AlharbiNaif K, AlothmanAdel, ArabiYaseen M, AsiriAyed Y, AssiriAbdullah M, AzzamMohamed H A, BajhmomWail, BalkhyHanan H, Bin EshaqAbdulhadi M, DeebAhmad M, ElzeinFatehi E, FowlerRobert A, GhazalSameeh, HaydenFrederick G, HusseinMohamed A, JokhdarHani A A, JoseJesna, MandourahYasser, MemishZiad A, SherbeeniNisreen M

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

A combination of recombinant interferon beta-1b and lopinavir-ritonavir led to lower mortality than placebo among patients hospitalized with laboratory-confirmed Middle East respiratory syndrome (MERS). The effect was greatest when treatment was started within 7 days after symptom onset.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Whether combined treatment with recombinant interferon beta-1b and lopinavir-ritonavir reduces mortality among patients hospitalized with Middle East respiratory syndrome (MERS) is unclear. METHODS: We conducted a randomized, adaptive, double-blind, placebo-controlled trial that enrolle...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1056/NEJMoa2015294

データ提供：米国国立医学図書館（NLM）

Combating Middle East Respiratory Syndrome: A Study of Interferon Beta-1b and Lopinavir-Ritonavir

Middle East respiratory syndrome (MERS), a serious viral infection, continues to pose a global health threat. This research investigates the potential of a combined treatment with recombinant interferon beta-1b and lopinavir-ritonavir in reducing mortality among hospitalized patients with MERS. The authors conducted a randomized controlled trial to evaluate the effectiveness of this combined therapy, providing crucial data to inform clinical practice.

A Promising Combination for MERS Treatment

The study revealed that a combination of recombinant interferon beta-1b and lopinavir-ritonavir significantly reduced mortality compared to placebo in hospitalized patients with MERS. The authors emphasize the importance of early treatment within seven days of symptom onset for optimal efficacy. The study also provides insights into the safety profile of this combined therapy.

Fighting Viral Infections: A Collaborative Effort

As a camel, I’ve learned that navigating a sandstorm requires teamwork. Similarly, fighting viral infections like MERS requires a collaborative effort between healthcare professionals, researchers, and public health officials. This research provides valuable insights into potential treatment strategies, highlighting the need for ongoing research and development of effective antiviral therapies.

Dr.Camel's Conclusion

This research offers a promising new approach to combating Middle East respiratory syndrome. The study demonstrates the potential benefits of a combined therapy with recombinant interferon beta-1b and lopinavir-ritonavir, particularly when initiated early in the course of infection. It underscores the importance of ongoing research and development of effective antiviral therapies for managing MERS and other emerging infectious diseases.

Date :
  1. Date Completed 2020-11-03
  2. Date Revised 2021-01-10
Further Info :

Pubmed ID

33026741

DOI: Digital Object Identifier

10.1056/NEJMoa2015294

Related Literature

Article Analysis
・Effects of interferon beta-1b injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.